In vivo cII, gpt, and Spi⁻ gene mutation assays in transgenic mice and rats

Mugimane G Manjanatha1, Xuefei Cao, Sharon D Shelton

  • 1Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.

Insights

This study details methods for transgenic mutation assays using Big Blue®, Muta™ mouse, and gpt-delta models. These assays identify genotoxic hazards and carcinogen mechanisms by analyzing reporter gene mutations in rodents.

Area of Science:

  • Toxicology and Genetic Toxicology
  • Molecular Biology and Carcinogenesis

Background:

  • Transgenic mutation assays are crucial for identifying genotoxic hazards and understanding carcinogen mechanisms.
  • Popular models include Big Blue® (rat/mouse), Muta™ mouse, and gpt-delta (rat/mouse), each utilizing distinct reporter genes.

Purpose of the Study:

  • To describe standardized methodologies for conducting mutation assays in established transgenic rodent models.
  • To provide a framework for the recovery, analysis, and quantification of mutations in reporter genes.

Main Methods:

  • Isolation of transgenes from tissue DNA.
  • Packaging of transgenes into lambda phage for bacterial infection.
  • Selective isolation and quantification of mutant plaques (cII, Spi⁻) and colonies (gpt).

Main Results:

  • Detailed procedures for implementing mutation assays in Big Blue®, Muta™ mouse, and gpt-delta systems.
  • Methodology allows for the quantification of mutations within specific reporter genes (cII, gpt) and loci (Spi⁻).

Conclusions:

  • The described methodologies enable robust characterization of genotoxic effects and carcinogen modes of action.
  • Further analysis of selected mutants can identify specific sequence alterations and large deletions.